ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.
Alnylam and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for rare genetic diseases.
Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.
lnylam Pharmaceuticals Inc., the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced the initiation of the ATLAS Phase 3 clinical program for fitusiran.
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
Merck & Co. has apparently gotten excited again about pushing the frontier with new RNA-based therapies. MRL Ventures, Merck’s early-stage biotech investment arm, has agreed to join The Baupost Group […]
